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Abstract: The Scottish Intercollegiate Guidelines Network (SIGN) guideline on delirium is a major 
advance on existing guidelines on this condition. This is particularly important given the evidence 
it is frequently under-diagnosed and inadequately managed despite being common and frequently 
associated with significant patient and carer distress and poor outcomes. The guidelines 
recommend using the 4A’s test to help detect delirium. A bundle of mostly non-pharmacological 
therapies minimise the risk of developing delirium and can help those who develop the condition. 
The importance of medical optimisation by an experienced professional in those at risk of delirium 
is highlighted with new recommendations for people in intensive care and surgical settings. There 
is guidance on follow-up of people with delirium, which should become routine. This commentary 
piece focusses on areas with the greatest potential to improve the experience and outcomes of those 
with delirium, and briefly discusses areas of ongoing uncertainty.   
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1. Background 
Delirium is a state of acute deterioration in mental functioning that occurs soon after acute 
medical illness, surgery, trauma, or a change in medications [1]. It causes significant patient and 
caregiver distress [2] and is associated with multiple serious complications, i.e., falling and/or 
worsened outcomes that increase the length of stay in hospitals and have higher rates of death and 
institutionalization [1]. Despite this, delirium is frequently underdiagnosed and poorly managed in 
clinical practice [3,4]. A systematic appraisal of existing guidelines revealed significant deficiencies 
in a wide range of quality measures, including applicability, editorial independence, currency, and 
visibility [5]. The development of a robust new guideline by the Scottish Intercollegiate Guidance 
Network (SIGN) is therefore a very welcome development [6]. It showcases the state-of-the-art 
practices in delirium prevention and management, providing a list of 12 evidence-based 
recommendations (see Section 1.1.) and expert opinion-based ‘good practice points’ (see Section 
1.2.), which are applicable to a wide range of healthcare settings. In this article, we discuss the 
recommendations that have the greatest potential to improve the experience and outcomes of those 
with delirium, while briefly highlighting areas of continuing uncertainty. 
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1.1. List of All Recommendations in the Scottish Intercollegiate Guidance Network (SIGN) Guideline on Risk 
Reduction and Management of Delirium 
Recommendations: 
• The 4AT tool should be used for identifying patients with probable delirium in emergency 
department and acute hospital settings. 
• Use of the 4AT tool could be considered for use in community or other settings for identifying 
patients with probable delirium. 
• For intensive care unit settings, Confusion Assessment Method – Intensive Care Unit 
(CAM-ICU) or Intensive Care Delirium Screening Checklist (ICDSC) should be considered to 
help identify patients with probable delirium. 
• Computed tomography (CT) brain scan should not be used routinely but should be considered 
in hospital patients with delirium in the presence of: 
o new focal neurological signs; 
o a reduced level of consciousness (not adequately explained by another cause); 
o a history of recent falls; 
o a head injury (patients of any age); 
o anticoagulation therapy. 
• Electroencephalogram should be considered when there is a suspicion of epileptic activity or 
non-convulsive status epilepticus as a cause of a patient’s delirium. 
• The following components should be considered as part of a package of care for patients at risk 
of developing delirium: 
o orientation and ensuring patients have their glasses and hearing aids; 
o promoting sleep hygiene; 
o early mobilization; 
o pain control; 
o prevention, early identification, and treatment of postoperative complications; 
o maintaining optimal hydration and nutrition; 
o regulation of bladder and bowel function; 
o provision of supplementary oxygen, if appropriate. 
• With the aim of avoiding excessively deep anesthesia, depth of anesthesia should be monitored 
in all patients aged over 60 years who are under general anesthesia during surgery expected to 
last for more than one hour. 
• The use of earplugs should be considered as part of a sleep-promotion strategy in intensive 
care. 
• All patients at risk of delirium should have a medication review conducted by an experienced 
healthcare professional. 
• Healthcare professionals should follow established pathways of good care to manage patients 
with delirium. 
o First, consider acute, life-threatening causes of delirium, including low oxygen level, 
low blood pressure, low glucose level, and drug intoxication or withdrawal. 
o Systematically identify and treat potential causes (medications, acute illness, etc), 
noting that multiple causes are common. 
o Optimize physiology, management of concurrent conditions, environment (reduce 
noise), medications, and natural sleep, to promote brain recovery. 
o Specifically detect, assess causes of, and treat agitation and/or distress, using 
nonpharmacological means only if possible (see Section 7 for pharmacological 
treatment). 
o Communicate the diagnosis to patients and caregivers, encourage involvement of 
caregivers, and provide ongoing engagement and support. 
Medicina 2019, 55, 491 3 of 6 
 
o Aim to prevent complications of delirium such as immobility, falls, pressure sores, 
dehydration, malnourishment, and isolation. 
o Monitor for recovery and consider specialist referral if not recovering. 
o Consider follow-up 
• Healthcare professionals should be aware that older people may have pre-existing cognitive 
impairment that may have been undetected or exacerbated in the context of delirium. 
Appropriate cognitive and functional assessment should be considered. Timing of this 
assessment must take into account persistent delirium. 
1.2. List of All ‘Good Practice Points’ in the SIGN Guideline on Risk Reduction and Management of Delirium. 
Good Practice Points: 
• A formal assessment and diagnosis must be made by a suitably trained clinician whenever 
patients with probable delirium are identified.  
• Where delirium is detected, patients and their family/caregivers should be informed of the 
diagnosis. 
• Where delirium is detected, the diagnosis of delirium should be clearly documented to aid 
transfers of care (e.g., handover notes, referral and discharge letters). 
• Consideration should be given to imaging patients with non-resolving delirium where no clear 
cause is identified or there are features to suggest primary central nervous system pathology. 
• Lumbar puncture should not be performed routinely on patients with delirium. 
• Ward moves should be avoided wherever possible for patients at risk of delirium. 
• Prior to surgery, patients and caregivers should be advised of the risk of developing delirium, 
to alleviate distress and help with management if it does occur. 
• Where possible, assistance should be sought from a patient’s relatives and caregivers to deliver 
care to reduce the risk of delirium developing. 
• Areas with patients at high-risk of delirium, such as trauma orthopaedic wards, should have 
protocols for commonly required medication (e.g., analgesia and anti-emesis) that contain 
choices for first-line treatments that minimise the risk of causing delirium. 
• Promote cognitive engagement, mobilization, and other rehabilitation strategies. 
• Patient records should be coded to highlight a previous episode of delirium so that hospital 
staff are aware of the increased risk on readmission. 
• Ensure that delirium is noted in the discharge letter for the primary care team. 
• All patients who have had delirium should be reviewed by the primary care team. 
• In patients who have experienced delirium in intensive care units (ICU), consideration should 
be given to follow-up for psychological sequelae including cognitive impairment. 
2. Detection of Delirium 
The SIGN guideline specifically recommends routinely using the 4AT tool [7] in emergency 
department and acute hospital settings and either the CAM-ICU or ICDSC [8] in ICU. There was 
insufficient evidence to make any firm recommendations in other settings, such as primary care, but 
the guideline suggests the 4AT could be used to identify those with probable delirium. The 4AT was 
the preferred tool due to its brevity, simplicity, applicability, and predictive properties. No specific 
staff training is required for its use and numerous independent validation studies have found high 
patient completion rates and sensitivity (86–100%) and specificity (65–82%) that compares favorably 
to other tools. It is important to note that most tools are essentially screening tools (e.g., 4AT, ICDSC) 
with higher sensitivity than specificity. Despite being a commonly used tool and closer to having 
‘diagnostic’ properties, the CAM is less favored in the guideline. This was principally due to its 
requirement for training and concerns that it lacks sensitivity in less experienced hands. The 
guideline states that it is important to follow any positive assessments with additional assessment by 
a suitably trained clinician against International Classification of Diseases (ICD-10) or Diagnostic 
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and Statistical Manual (DSM-5) criteria. It also states that a negative result does not rule out delirium 
completely, as delirium classically fluctuates or can occur after admission.  
Although this is helpful and should minimize under-diagnosis of delirium, some questions 
remain. Should all admissions to hospital be screened or should detection tools be targeted, for 
example to those aged over 65? How should we monitor for incident delirium? In what patient 
groups and how frequently? Do available tools have utility in community and long-term care 
settings? There is currently insufficient evidence to answer these questions. 
3. Managing Delirium 
Reinforced throughout the SIGN guideline is the importance of making the diagnosis of 
delirium and communicating it to the patient, their relatives, and all relevant healthcare 
professionals involved in their care. This includes clearly documenting the diagnosis in the clinical 
record and any transfer and discharge documentation. There are helpful sections on communication 
and patient education, with resources and checklists of important points to consider helping patients 
and relatives become better informed and more actively involved in their condition and treatment. 
This is especially pertinent where individuals lose their capacity to consent to investigation and 
treatment due to delirium. 
Moreover, the SIGN guidelines acknowledge that the evidence-base for effective treatments in 
delirium is weak. Nevertheless, it recommends following an established, multi-component pathway 
of interventions to help identify underlying causes, since delirium is usually multi-factorial. Though 
no specific pathway is recommended, a couple of potentially suitable examples (the TIME bundle 
and the Scottish Delirium Association pathway [9]) are included as appendices. There is a wealth of 
information on appropriate clinical investigations to look for underlying causes, but interestingly 
some of the focus of the recommendations are on the futility of some over-used tests. For example, 
CT scans of the head and lumbar puncture should not be used routinely due to low diagnostic yield, 
though they are still recommended in some specific situations, for example where there are 
localizing signs on neurological examination to suggest a brain lesion. Conversely, the guidelines 
acknowledge recent evidence suggesting epileptic activity and non-convulsive status in delirium is 
higher than it is widely appreciated. Though it does not recommend its routine use, the guidelines 
recommend that electroencephalography (EEG) should be undertaken when there is clinical 
suspicion of epilepsy or non-convulsive status as a cause of delirium. This may also include its use in 
unexplained, non-resolving delirium. 
The guidelines do not recommend routine use of any pharmacological treatment of delirium 
and particularly highlight a recent Cochrane review finding that antipsychotics did not reduce 
delirium severity, duration, or alter mortality [10] in non-ICU settings. Evidence of their efficacy in 
the ICU was insufficient despite some limited evidence they might reduce duration of delirium [11]. 
There was insufficient evidence to recommend use of dexmedetomidine, acetylcholinesterase 
inhibitors, or benzodiazepines. However, use of urgent pharmacological intervention is advocated 
in patients with ‘intractable distress’ or where the safety of the patient or others is compromised. 
Finally, the guidelines make clear recommendations that all patients with delirium should be 
followed up in primary care to check for common sequela, including depression, post-traumatic 
stress disorder and enduring cognitive impairment that may lead to a diagnosis of dementia. 
4. Risk Reduction and Prevention of Delirium 
Since treatments for delirium are of limited proven efficacy, many of the guideline 
recommendations focus on preventing delirium in those at high-risk of developing it. A 
multi-component non-pharmacological intervention promoting early mobilization, regular 
orientation, minimizing sensory impairment, and optimizing hydration and nutrition significantly 
reduces incident delirium rates by almost a third, but only in those at higher risk [12,13]. The 
definition of a ‘high-risk’ population is undefined in the guideline due to lack of consensus but, 
typically, studies showing efficacy were undertaken in older people (usually defined as over 65 
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years old), those with pre-existing cognitive impairment, or adults of any age in ICU. There are a 
number of specific recommendations for patients in ICU, such as provision of hearing plugs to 
minimize sleep disturbance, and for those undergoing major surgery, such as minimizing depth of 
anesthesia through intra-operative monitoring. Recommendations around pharmacological risk 
reduction and prevention are focuses on avoiding or minimizing doses of medications known to 
induce or exacerbate delirium, such as benzodiazepines, opioids, and anticholinergics. All patients 
at risk of delirium should have their prescriptions optimized by an experienced professional. 
Clinical departments with high prevalence of delirium are encouraged to develop protocols for 
commonly required medications (e.g., analgesia) that contain treatments that minimize the risk of 
causing delirium. As for the treatment of delirium, no specific pharmacological therapies to prevent 
delirium are recommended, including some that are routinely used in some clinical areas, such as 
antipsychotics and melatonin. Although an early draft of the guideline suggested peri-operative 
dexmedetomidine could be considered in high-risk patients, the final version of the guideline 
concludes the evidence for its efficacy is not good enough to warrant any recommendation. This 
decision centered around concerns that trials showing benefit were largely limited to those where 
the control group had received higher doses of benzodiazepines and other sedatives that are known 
to cause delirium. 
5. Comparison between SIGN and National Institute of Healthcare and Care Excellence (NICE) 
Guidelines 
Although the new guideline is broadly similar to the National Institute of Healthcare and Care 
Excellence (NICE CG 103, 2010) guidelines on delirium, there are some important differences. SIGN 
is more specific about how best to detect delirium, particularly in non-ICU settings. The 
recommendations for preventing delirium are essentially the same, though the updated SIGN 
guideline includes a stronger evidence base for multi-component interventions from recent studies. 
The new guidelines on investigating and treating delirium are much more detailed than that in 
NICE, with a stronger emphasis on non-pharmacological interventions and encouraging the active 
participation of family and caregivers. Conversely, the recommendations around pharmacological 
treatment are more reserved, with no specific recommendation for haloperidol or any other agent 
due to the lack of evidence of efficacy. Recommendations on follow-up are also included only in the 
SIGN guidelines. 
6. Implementing the Guideline and the Future of Delirium Care 
Guidelines have potential to do harm [14], especially if they are applied indiscriminately or 
used as a substitute for clinical reasoning. However, the SIGN guideline reinforces throughout the 
need for person-centered care and judicious application of all recommendations according to the 
needs of the individual patient. It includes recommendations on implementation and quality 
assurance for Scottish health boards that could easily be adopted elsewhere. It helpfully lists 
opportunities for future research on important clinical questions that remain unanswered, such as 
the impact of follow-up clinics on the mental health of people who have experienced delirium. It 
promises to be a landmark publication to help bridge the gap between desired and actual clinical 
practice [15]. Widespread implementation of its recommendations would have a major beneficial 
impact on the prevalence of delirium and the poor outcomes and experiences for those with the 
condition. 
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